Podcasts about vascepa

In this 194th in a series of live discussions with Bret Weinstein and Heather Heying (both PhDs in Biology), we discuss the state of the world through an evolutionary lens. In this episode we discuss the 2023 Nobel Prize in Physiology or Medicine, which was awarded for nucleoside base modifications that enabled the development of mRNA vaccines against COVID-19. We discuss the innovation for which the prize was awarded, what some of the known effects are, and what has been claimed about the (lack of) effects. We review some Nature news articles, including the finding that mRNA vaccines are linked to unexpected menstrual events. And we compare the costs and benefits of eating fish, supplementing with fish oil, and pharmaceutical drugging with Vascepa, and discuss connections between the three. ***** Our sponsors: Seed: Start a new healthy habit today with Seed probiotics. Use code darkhorse at https://seed.com/darkhorse to get 25% off your first month of Seed's DS-01® Daily Synbiotic. UnCruise: Get $500 off any adventure cruise on a small ship into destinations including Galapagos, Panama, Alaska, and the San Juan Islands: https://uncruise.com/pages/darkhorse/ Mindbloom: at-home ketamine therapy. Use code DARKHORSE at www.Mindbloom.com to receive $100 off your first six session program. ***** Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.com/ Heather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.com Our book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://a.co/d/dunx3at Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org ***** Q&A Link: https://rumble.com/v3my788-your-questions-answered-bret-and-heather-194th-darkhorse-podcast-livestream.html Mentioned in this episode: Nobel press release: https://www.nobelprize.org/prizes/medicine/2023/press-release/ Chinese journalist asking Nobel committee about safety: https://x.com/refugeofsinner5/status/1709225153429737584 Nobel laureate Weissman discussing safety of mRNA shots in January 2021: https://x.com/TheChiefNerd/status/1708912252487684588 Fraiman et al 2022. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine, 40(40): 5798-5805:https://www.sciencedirect.com/science/article/pii/S0264410X22010283 COVID vaccines linked to unexpected vaginal bleeding. Nature News 9-25-23:https://www.nature.com/articles/d41586-023-02996-6 Covid vaccines and safety: what the research says. Nature News Explainer 2-16-21: https://www.nature.com/articles/d41586-021-00290-x How Covid unlocked the power of RNA vaccines (“Side effects can be troubling.”). Nature News feature 1-12-21: https://www.nature.com/articles/d41586-021-00019-w Fish, fishy, and fish adjacent: https://open.substack.com/pub/naturalselections/p/fish-fishy-and-fish-adjacentJob opportunity: https://amarincorp.com/job/key-account-managerSupport the show

For more information, contact us at 859-721-1414 or myhealth@prevmedheartrisk.com. Also, check out the following resources: ·Newsletter Sign Up·Purchase an Appointmen Today!·PrevMed's Locals·PrevMed's Rumble·PrevMed's website·PrevMed's YouTube channel·PrevMed's Facebook page·PrevMed's Instagram·PrevMed's LinkedIn·PrevMed's Twitter ·PrevMed's Pinterest

The landmark Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT®) was a global outcomes study designed to assess the cardioprotective efficacy and safety of VASCEPA® (icosapent ethyl) as an add-on to statin therapy in reducing major cardiovascular (CV) events in a high-risk patient population. Join endocrine experts Eliot A. Brinton, MD, FAHA, FNLA, FACE, President of Utah Lipid Center, and Past President, of the American Board of Clinical Lipidology, and Betul Hatipoglu MD, Professor of Medicine at CWRU School of Medicine, and Medical Director for Diabetes & Obesity Center at University Hospital Cleveland Medical Center, to learn about the results of the REDUCE-IT® trial and new developments in CV prevention.

Printable Tip Sheet: Diabetes and Cardiovascular Disease: Are Statins Enough?Recorded Webinar: Focus on Persistent Cardiovascular RiskPrescribing Information and more information on VASCEPA.This podcast episode and the participation of Dr. Jennifer Goldman is sponsored by Amarin Pharma, Inc., makers of VASCEPA® (icosapent ethyl). To learn more about VASCEPA and to access the full prescribing information, visit VASCEPA.com. 

For more information, contact us at 859-721-1414 or myhealth@prevmedheartrisk.com. Also, check out the following resources:  ·PrevMed's website·PrevMed's YouTube channel·PrevMed's Facebook page

If you have a high TG level, there are ways to lower it—a healthy diet, lose weight, address medical conditions like prediabetes/diabetes. Sometimes, the doctor may prescribe meds, like Vascepa (icosapent ethyl). But is taking Vascepa worth it?For more information, contact us at 859-721-1414 or myhealth@prevmedheartrisk.com. Also, check out the following resources:  ·PrevMed's website·PrevMed's YouTube channel·PrevMed's Facebook page

Goop London closes, Bon Appetit video relaunches, and we talk vegan cheese, Vascepa, Theragun, Wim Hof, marriage problems, subscription services and more! 

On this episode, we revisit the management of of dyslipidemia. We review the basic pathophysiology of atherosclerosis and the four statin treatment groups. We also discuss where ezetimibe and PCSK9 inhibitors fit into the treatment regimens. We close with an overview of the EVAPORATE trial with icosapent ethyl (Vascepa) and the bempedoic acid (Nexletol) CVOT called CLEAR Outcomes. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable Power Point slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.   

This week's monologue touches on the credibility of expert speakers, evaluating the COVID-19 lockdown as health policy, and the anti-affirmative action white paper written by Dr. Norman Wang and its controversy. In the second half of the episode we interview Professor Darrel Francis of Imperial College London on COVID-19 cardiology and Vascepa. Anti-Affirmative Action: doi.org/10.1161/JAHA.120.015959 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

We have a number of topics for you this week! Among them, we cover the issue of colon cancer screening, especially in the light of Chadwick Boseman's recent passing. We interview Jonathan Darrow, an Assistant Professor at Harvard Medical School and faculty at Brigham and Women's Hospital, on patent litigation and the recent patent appeal for Vascepa. Finally, we interview Dr. Toby Richards, Professor of Surgery, on running clinical trials and, specifically, the results of his recent trial PREVENTT, out now in The Lancet. PREVENTT: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31539-7/fulltext Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Patent management is the hot topic of this episode. The focus is on AMARIN's leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019. Healthcare consultant Jared Wolff is joined by Bruna Favetta who has experience with the development of patent strategy, and Kate Jones who has a background in law. AMARIN has recently found themselves in unchartered territory as VASCEPA's drug patent is being challenged by generic producers, this episode explores: Why this case of VASCEPA is significantHow this may set a future precedent in drug patent law  Thanks for listening!

The District Court of Nevada rules that Amarin's Vascepa patents are invalid, but an appeal has already been filed! Axsome therapeutics fails their Phase 3 trial in treatment-resistant depression, but plans on moving forward with another trial. Finally, I talk about Athersys and their Multistem Cell Therapy for Acute Respiratory Distress Syndrome after receiving a "Highly Relevant" designation from the Biomedical Advanced Research and Development Authority (BARDA) of United States HHS.For more details on the Amarin patent case, check out Zachary Silbersher's blog here: https://www.markmanadvisors.com/blog/2020/3/31/can-amarin-win-on-appeal-in-the-vascepa-patent-litigationDisclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech

03/06/20 - In this episode, Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) offer the latest update on the Coronavirus. There seems to be two strains, one that is a little milder and seems to have affected 80% of those diagnosed. Keep in mind that 17-thousand Americans died from the last Pandemic, which was in 2009 and 2010. Dr. Ken explains the symptoms to look for, in detail. A new study shows that people with irregular sleep patterns are more prone to Heart Disease than others. Do you know your Body Mass Index? Dr. Ken explains how to calculate it and the recommended guidelines. Fish oil is also known to help keep your heart healthy and will not cause Cancer. The FDA has recently approved a drug that can help with Heart Disease, Vascepa. Plus, lots more tips and great ideas to help you maintain your Good Health.

Hosted by: Dr. Danielle Belardo  Instagram: @daniellebelardomd Twitter: @dbelardomd Facebook: Dr. Danielle Belardo, MD   Produced by: Dr. Kasey Johnson Instagram: @drkaseyjohnson   Also be sure to follow today's guest, Dr. Martha Gulati! Instagram: @drmarthagulati Twitter: @drmarthagulati   In this brilliant episode with expert Cardiologist Dr. Martha Gulati, in less than 90 minutes you will learn everything you ever wanted to know about preventing, diagnosing, and treating cardiovascular disease. We discuss the epidemic of cardiovascular disease in women, and learn how pregnancy can elucidate certain risk factors for heart disease down the road. We discuss what’s hot in prevention, from coronary artery calcium scores to PCSK9 inhibitors, SGLT2 inhibitors, Vascepa and more!    Martha Gulati, MD, MS, FACC, FAHA, FASPC is a Professor of Medicine and the Chief of Cardiology at theUniversity of Arizona (Phoenix). She held the Sarah Ross Soter Chair in Women’s Cardiovascular Health and was the Section Director for Women’s Cardiovascular Health and Preventive Cardiology at The Ohio State Universityuntil 2015. She is the author of the best-seller, “Saving Women’s Hearts”. She is the Editor-in-Chief of the American College of Cardiology “CardioSmart”, the patient education and empowerment initiative. She serves as the chair of the national chest pain guidelines. Her exceptional commitment to the study of women and cardiac diseases has won her numerous awards and distinctions, including being named by Crain’s Chicago Business as one of Chicago’s “Top 40 under 40,” a list that honors 40 outstanding individuals who have made a major impact in their respective industries before the age of 40. In 2011, she received the first CREDO (Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Outcomes) Award from the American College of Cardiology that was given to honor her contributions to improve cardiovascular healthcare of women patients. In 2012, she was awarded the National Red Dress Awardfor her efforts in raising awareness of heart disease in women and advancing research in this field. In 2019, she was chosen as the most influential woman in Arizona and received the 2019 American College of Cardiology’s Bernadine Healy Award for her leadership and accomplishment in the field of cardiovascular disease in women. Dr. Gulati is passionate about the study of women and heart disease and prevention of heart disease.  She is the principal investigator of the St. James Women Take Heart Project, a study examining cardiac risk factors in women, which set new standards for women’s fitness levels and heart rate response to exercise in women. She also is a co-investigator on the Women Ischemic Syndrome Evaluation (WISE) and previously served as a co-investigator on the Women’s Health Initiative (WHI).   She is a member of numerous advisory boards and societies, including the American Heart Association(AHA), the American College of Cardiology and the American Society of Preventive Cardiology (ASPC). She serves on the board of the ASPC, the Phoenix chapter of the American Heart Association and the board of WomenHeart.  She has published articles in peer-reviewed publications, including The New England Journal of Medicine, Circulation, and Journal of theAmerican Medical Association (JAMA).  Her research has been featured in hundreds of newspapers across the world, including The New York Times and USA Today. She has also been featured on Oprah and been feature on CBS National News, The Today Show, Canada AM, in addition to many others. She recently was listed on the Marquis 2019 Who’s Who in America, Who’s Who in the World, and Who’s Who in American Women. Dr. Gulati completed medical school at the University of Toronto, Canada.  She went on to complete her internship, residency, and cardiology fellowship at the University of Chicago.  She received a Master in Science at the University of Chicago and is a fellow of the American College of Cardiology and the American Heart Association.  She is board certified in cardiovascular disease.

Here are the links for everything discussed in Episode 14. Xtandi added indication Xeljanz XR added indication Approval of Padcev for urothelial cancer Approval of Vyondys 53 for Duchenne Muscular dystrophy Vascepa approval to reduce the risk of cardiovascular events. Connect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

Vascepa approved for cardiovascular risk reduction The FDA’s decision on cutting events in high-risk patients was based primarily on the REDUCE-IT trial. ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding Novel oral anticoagulants may be preferred over warfarin in patients with diabetes and AFib. HHS drug importation proposals aim to address high costs Trump administration drops key health care proposal on day of impeachment vote. End ‘therapeutic nihilism’ in care of older diabetic patients, says expert ‘It’s not hyperglycemia that’s killing people; it’s heart disease and renal disease.’ *  *  *   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeTweets

Amarin finally receives label expansion for Vascepa, which can now be marketed to patients with Triglyceride levels of greater or equal to 150mg/dl and existing Cardiovascular Disease or Diabetes Mellitus plus two other risk factors for CVD. In this video, I go through what I think is the potential market for this drug and the company's valuation.I also talk about a number of other companies that had updates at ASH2019 or around that time, including BLUE, FATE, DTIL, KOD, SRPT, SNY.Follow me on twitter @matthewlepoire Email me at matthewlepoire@gmail.com www.breakingbiotech.comRelevant sources: Fan W. Diabetes. 2018:67(Suppl 1) 2019 AHA Heart Disease and Stroke Statistics Fan W. J Clin Lipidol. 2018:13(1) Einarson TR. Cardio Diabetol. 2018 17(83)Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech

Vascepa was just approved by the FDA to reduce cardiovascular risk among certain patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. In a recent study Vascepa significantly reduced the risk of death due to cardiovascular causes, heart attack, and stroke in patients who remained at increased risk despite statin therapy.

Monologue Dr. Joel Wallach begins the show discussing mental health issues. Outlining several mental health challenges such as Autism. Contending they are all due to nutritional defciencies. Stating that if nutrients were put in the water these challenges would stop. Citing the Texas study where two counties were compared the numbers of violent acts. One county had a lot more vionet acts. But were missing a certain mineral in the water. The county with much less violence did have the mineral in it's water. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss a news article regarding the FDAs approval of Vascepa. The drug is touted to help prevent heart attacks, strokes and death in people with cardiovascular disease. Doc asserts that people should just Youngevity's EFAs. As the EFA Plus contains fish oils and are easily absorbed. Callers Venita has several health challenges including high blood pressure, weight gain and hypothyroidism. David has questions concerning a skin rash in his genital area. Roger is experiencing peripheral neuropathies in his hands and feet. Call Dr. Wallach's live radio program weekdays from noon until 1pm pacific time at 831-685-1080 or toll free at 888-379-2552.

Survival Medicine Podcast #375 In survival, the medicines eventually run out no matter how well you’ve prepared if the disaster knock you off the grid for long enough. This is especially true for drugs for which you can only stockpile a limited quantity, simply because they’re too expensive. One item that isn’t too expensive is fish oil, commonly available in supplement or in FDA-approved prescription items. The scientific data shows that they can reduce triglycerides in your blood, a factor in coronary artery disease, and perhaps help in other ways. So what is fish oil and is it of any use off the grid? Should you accumulate it in quantity in your medical storage. That's your decision, but you'll know a lot more about it after listening to Dr. Joe Alton of doomandbloom.net! Also, Dr. Alton answers a question from someone suffering from symptoms similar (but not exactly) to carpal tunnel syndrome. Could he have Guyon's Syndrome instead? Learn about it in this episode of the new-format Survival Medicine Podcast! Wishing you the best of health in good times or bad, Joe Alton MD/Amy Alton ARNP Hey, show your support for our mission to put a medically prepared person in every family by subscribing to our website at doomandbloom.net and checking out Nurse Amy's often-imitated, never-equaled medical kits and supplies at store.doomandbloom.net!  

Survival Medicine Podcast #375 In survival, the medicines eventually run out no matter how well you’ve prepared if the disaster knock you off the grid for long enough. This is especially true for drugs for which you can only stockpile a limited quantity, simply because they’re too expensive. One item that isn’t too expensive is fish oil, commonly available in supplement or in FDA-approved prescription items. The scientific data shows that they can reduce triglycerides in your blood, a factor in coronary artery disease, and perhaps help in other ways. So what is fish oil and is it of any use off the grid? Should you accumulate it in quantity in your medical storage. That's your decision, but you'll know a lot more about it after listening to Dr. Joe Alton of doomandbloom.net! Also, Dr. Alton answers a question from someone suffering from symptoms similar (but not exactly) to carpal tunnel syndrome. Could he have Guyon's Syndrome instead? Learn about it in this episode of the new-format Survival Medicine Podcast! Wishing you the best of health in good times or bad, Joe Alton MD/Amy Alton ARNP Hey, show your support for our mission to put a medically prepared person in every family by subscribing to our website at doomandbloom.net and checking out Nurse Amy's often-imitated, never-equaled medical kits and supplies at store.doomandbloom.net!  

Icosapent ethyl cost effective in REDUCE-IT analysis Treatment with the fish-derived drug Vascepa for CV event reduction is more effective and less costly than placebo. *  *  *   Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 *  *  *   DAPA-HF: Dapagliflozin benefits regardless of age, HF severity The SGLT2 inhibitor had similar efficacy in the elderly and across the spectrum of baseline symptom status. Colchicine cut post-MI CVD events Colchicine fulfilled the promise first seem in CANTOS that anti-inflammatory treatment can reduce cardiovascular disease events. Cardiac arrests peak with pollution in Japan The incidence of out-of-hospital cardiac arrests in Japan increased on days when counts of particulate matter spiked from the day before. *  *  *   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeTweets

Amarin's shares rocketed higher after a key FDA committee recommended expanding the label of its triglycerides lowering drug, Vascepa, to include data showing it can reduce the risk of heart attack and stroke. Meanwhile, shares in CRISPR Therapeutics and partner Vertex Pharmaceuticals are also soaring following the release of interim, early-stage results for its gene-editing therapy for beta thalassemia and sickle cell disease therapy. Stocks: AMRN, CRSP, VRTX Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA regarding their EPA medication (Vascepa) for the lowering of triglycerides. I believe the difficulty #AMRN has had with the FDA in the past has made the market concerned about Vascepa's future given recent announcement of an advisory committee meeting for label expansion of Vascepa. I also talk about Sarepta, Novartis and Gilead.This is not investment advice. Please do your own due diligence before ever investing in equity markets.www.breakingbiotech.com http://epadruginitiative.com/press/why-the-fda-got-it-wrongSupport Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication. Read more about the stories in this podcast: FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients: https://www.ajmc.com/newsroom/fda-approves-gene-therapy-with-21m-price-tag-for-spinal-muscular-atrophy-in-pediatric-patients Serious Health-Related Suffering to Nearly Double by 2060, Highlighting Need to Ramp Up Palliative Care Efforts: https://www.ajmc.com/focus-of-the-week/serious-healthrelated-suffering-to-nearly-double-by-2060-highlighting-need-to-ramp-up-palliative-care-efforts What We're Reading: FDA Grants Priority Review for Amarin's Vascepa; HHS Rule Challenged; Military Mental Health Proposal: https://www.ajmc.com/newsroom/what-were-reading-fda-grants-priority-review-for-amarins-vascepa-hhs-rule-challenged-military-mental-health-proposal Amarin's High-Dose Fish Oil Pill Cuts Total CV Event Risk 30% in Study: https://www.ajmc.com/conferences/acc-2019/amarins-highdose-fish-oil-pill-cuts-total-cv-event-risk-30-in-study The American Journal of Managed Care—May 2019: https://www.ajmc.com/journals/issue/2019/2019-vol25-n5 Open Doors to Primary Care Should Add a “Screen” to Reduce Low-Value Care: https://www.ajmc.com/journals/issue/2019/2019-vol25-n5/open-doors-to-primary-care-should-add-a-ldquoscreenrdquo-to-reduce-lowvalue-care American Society of Clinical Oncology Annual Meeting 2019: https://www.ajmc.com/conferences/asco-2019

In this week’s episode, John reviews some pharma breakthroughs—along with one major setback—and discusses the bold statement by the Department of Justice (DOJ) regarding the Affordable Care Act (ACA). Highlights include: The Department of Justice issued a letter stating that it agrees with a federal judge who struck down the entire ACA as unconstitutional. The FDA approved the first drug to treat postpartum depression: Sage Therapeutics’ Zulresso (brexanolone). Amarin Corp. presented updated results for its ongoing Vascepa (icosapent ethyl) clinical trial, REDUCE-IT, at the American College of Cardiology Annual Meeting. Biogen is scrapping its investigational treatment for Alzheimer’s disease, and is canceling its Phase III ENGAGE and EMERGE clinical trials. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate. Medical conferences: doi.org/10.1001/jama.2012.360

Amarin recently published data from their REDUCE-IT cardiovascular outcomes trial. Their EPA medicine, Vascepa, showed a 25% relative risk reduction compared to placebo. EPA is an omega-3 fatty acid that previously showed a 19% relative risk reduction in cardiovascular outcomes in a Japanese study (JELIS, 2007). Amarin saw a hazard ratio of 0.75 in their primary endpoint, which evaluated cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina. In this video, I go through two critiques of the study: 1) Lack of mechanistic insight 2) Mineral oil use in the placebo group I believe Vascepa is likely to get FDA approval for the indication of reducing cardiovascular disease in patients with over 150mg/dl Triglycerides on statin therapy. This is not investment advice, do your own due diligence.Relevant links: https://investor.amarincorp.com/ https://www.nejm.org/doi/full/10.1056/NEJMoa1812792 https://www.nejm.org/doi/full/10.1056/NEJMe1814004

-Amarin's EPA medicine, Vascepa, recently showed a 25% relative risk reduction in newly announced data from the cardiovascular outcomes trial, REDUCE-IT. -Today I breakdown the results and talk about how it compares to other CVOT data and whether Amarin is likely to rival companies with a LDL-c lowering drug pipelines.this is not investment/trading advice Follow me @matthewlepoire www.breakingbiotech.comRelevant links: http://investor.amarincorp.com/node/15741/pdf http://investor.amarincorp.com/system/files-encrypted/nasdaq_kms/assets/2018/09/27/10-23-58/AMRN%20Investor%20Deck%20Sept%20Post%20R-IT%20v3.pdf https://www.ncbi.nlm.nih.gov/pubmed/29935936

Today in FirstWord: